Thrivent Financial For Lutherans Allogene Therapeutics, Inc. Transaction History

Thrivent Financial For Lutherans

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$4.53 - $6.74 $729,203 - $1.08 Million	-160,972 Reduced 55.41%	129,535 $644,000
Q1 2023 May 17, 2023	SELL	$4.92 - $8.21 $818,535 - $1.37 Million	-166,369 Reduced 36.41%	290,507 $1.44 Million
Q4 2022 Feb 08, 2023	BUY	$5.62 - $11.11 $1.63 Million - $3.23 Million	290,286 Added 174.25%	456,876 $2.87 Million
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $1.27 Million - $2.13 Million	123,176 Added 283.72%	166,590 $1.8 Million
Q2 2022 Aug 16, 2022	SELL	$6.78 - $12.28 $256,778 - $465,080	-37,873 Reduced 46.59%	43,414 $494,000
Q1 2022 May 13, 2022	SELL	$7.65 - $15.29 $574,147 - $1.15 Million	-75,052 Reduced 48.01%	81,287 $740,000
Q4 2021 Feb 16, 2022	BUY	$13.13 - $24.52 $1.34 Million - $2.5 Million	102,160 Added 188.56%	156,339 $2.33 Million
Q3 2021 Nov 15, 2021	BUY	$21.01 - $27.64 $269,432 - $354,455	12,824 Added 31.01%	54,179 $1.39 Million
Q2 2021 Aug 19, 2021	BUY	$23.49 - $35.8 $971,428 - $1.48 Million	41,355 New	41,355 $1.08 Million

163

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $233M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.